U.S.
Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact
Clearmind Medicine; Mary-Elizabeth Gifford; Chief of Global Impact; psychedelic medicine; US partnerships; governmental engagement; regulatory advocacy; biotech company; clinical trials; mental health
Drugmakers Push US Expansion After Trump’s 100% Pharma Tariff Threat
Trump tariff; pharmaceuticals; US manufacturing; branded drugs; drugmakers; Genentech; Roche; Novo Nordisk; Section 232; supply chain
Roche in Talks With US on Drug Pricing; Sets Out Pipeline and Dealmaking Ambitions
Roche; drug pricing; US government; pharmacy benefit managers; direct-to-consumer sales; pipeline; dealmaking; US investment; manufacturing; gene therapy; R&D; Ocrevus; Hemlibra; Vabysmo
Biopharma Deal Activity Shows Uptick in Q3 2025: Signs of Recovery and Emerging Trends
biopharma; Q3 2025; deal activity; M&A; licensing; therapeutic diversification; early-stage assets; China; US; Europe; Metsera; Verona Pharma; Merus; high-value deals
US Government Backs In Vivo Cell Therapy Startup with Major Funding
federal funding; in vivo cell therapy; startup; immunoVec; US government
Ansa Biotechnologies Raises $54.4M in Series B to Scale US DNA Synthesis Manufacturing
Ansa Biotechnologies; Series B financing; DNA synthesis; Cerberus Ventures; US manufacturing; biotechnology; synthetic DNA; fundraising
AstraZeneca Plans Direct US Stock Listing While Maintaining UK Headquarters
AstraZeneca; US stock listing; NYSE; London Stock Exchange; Nasdaq Stockholm; American Depositary Receipts; capital markets; pharmaceutical industry; shareholders; UK headquarters
Bristol Myers Squibb to Launch Schizophrenia Drug Cobenfy in UK at US Price
Bristol Myers Squibb; Cobenfy; schizophrenia; UK launch; drug pricing; US list price; NHS; cholinergic receptors; antipsychotic; 2026
AbbVie Extends Rinvoq Exclusivity to 2037, Delaying Generics in U.S.
AbbVie; Rinvoq; patent settlement; generic competition; exclusivity extension; upadacitinib; US market; pharmaceutical litigation
Japan Wins Exemption for Generics in US-Japan Trade Deal
Japan; US Trade Deal; generic pharmaceuticals; tariff exemption; semiconductor supply chains; Trump administration